Patent · US Active

Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses

US11402381B2 · kind B2 · utility

0Cited by

2References

8Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Friedemann Krause · Penzberg, DE
Vinzent Rolny · Munich, DE
Farshid Dayyani · Irvine, US
Achim Escherich · Hergiswil, CH
Birgit Wehnl · Munich, DE
Ying He · Norwalk, US
Julia Riedlinger · Ottobrunn, DE
Felix Herth · Heidelberg, DE
Thomas Muley · Heidelberg, DE

Key dates

Filing date	Apr 13, 2018
Grant date	Aug 2, 2022
Priority date	—
Expiry date	Jun 14, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/70596
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.